ArticleNature2023
CRISPR screens decode cancer cell pathways that trigger γδ T cell detection.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
14.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 85 citations in OpenAlex.
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.Nature reviews. Clinical oncology · 2026Review
- γδ T cells in colorectal and liver cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- γδ T cells and cancer.The Journal of clinical investigation · 2026Review
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- Phosphoantigen-driven dissociation of butyrophilin oligomers activates γδ T cells.Cell discovery · 2026Article
- Intracellular lipid droplets positively regulate the dormancy of colorectal cancer cells depending on ELF1-ACSL5 signaling.Journal of experimental & clinical cancer research : CR · 2026Article
- Metformin sensitizes esophageal squamous cell carcinoma to Vγ9Vδ2 T cell-mediated cytotoxicity by upregulating BTN3A1 and BTN2A1.Cell death & disease · 2026Article
- Glucose restriction reprograms lipid metabolism and enhances immunotherapy through ZNRF3-Wnt-SCD signaling axis.Journal for immunotherapy of cancer · 2026Article
- Mitochondrial metabolism and signaling direct dendritic cell function in antitumor immunity.Science (New York, N.Y.) · 2026Article
- γδ T cells at the interface of innate and adaptive immunity in cancer.Journal for immunotherapy of cancer · 2026Review
- Re-Tooling of γδ T Cells for Cancer Immunotherapy Using Advanced Manufacturing and Genetic Engineering.Cells · 2026Review
- nf-core/crisprseq: a versatile pipeline for comprehensive analysis of CRISPR gene editing and screening assays.NAR genomics and bioinformatics · 2026Article
- Variation in guide RNA library representation results in gene effect score bias in genome-wide CRISPR screens.BMC genomics · 2026Article
- Single-cell profiling reveals diverse γδ T cell subsets in ulcerative colitis.Science immunology · 2026Article
- Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy.Oncology research · 2026Article
- High-throughput screening to engineer optimal T cell therapies: current knowledge and future prospects.Frontiers in oncology · 2026Review
- Translational potential of γδ T cells in hematologic diseases: from immunobiology to therapeutic innovation.Frontiers in immunology · 2026Review
- Review
- The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing.Frontiers in immunology · 2026Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors at 6 institutions in 2 countries.
Murad R MamedovGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. murad.mamedov@ucsf.edu.ORCID 0000-0002-1543-3330
Shane Vedova *Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Jacob W Freimer *Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0001-9239-2272
Avinash Das SahuDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Amrita RameshDepartment of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, USA.
Maya M ArceGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Angelo D MeringaCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
Mineto OtaGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Peixin Amy ChenGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0001-9930-1249
Kristina HanspersInstitute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0001-5410-599X
Vinh Q NguyenGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Kirsten A TakeshimaGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Anne C RiosPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Jonathan K PritchardDepartment of Genetics, Stanford University, Stanford, CA, USA.ORCID 0000-0002-8828-5236
Jürgen KuballCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0002-3914-7806
Zsolt SebestyenCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
Erin J AdamsDepartment of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-6271-8574
Alexander MarsonGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. alexander.marson@ucsf.edu.ORCID 0000-0002-2734-5776
Gladstone Institutes · USUniversity Medical Center Utrecht · NLUniversity of Chicago · USHarvard University · USOncode Institute · NLStanford University · US
Funding
MEDICAL SCIENTIST TRAININGT32GM007281 · NIGMS · UNIVERSITY OF CHICAGO · PI CLARK, MARCUS RAMSAY · 1985 to 2022
$32.1MIntegration of genetic association mapping and functional data to elucidate genetic mechanisms of diseaseR01HG008140 · NHGRI · STANFORD UNIVERSITY · PI JONATHAN K PRITCHARD · 2016 to 2026
$7.3MMedical Scientist National Research Service AwardT32GM150375 · NIGMS · UNIVERSITY OF CHICAGO · PI Raghavendra G Mirmira · 2023 to 2026
$5.5MRestorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher, Anita Sil · 2020 to 2026
$4.5MMolecular and functional investigation of the role of CD1 in gamma delta T cell surveillanceR01AI155984 · NIAID · UNIVERSITY OF CHICAGO · PI ADAMS, ERIN JUNE · 2020 to 2024
$2.7MPUMAS - A Pipeline program for comMUnity college students Advancing in the SciencesR25HL121037 · NHLBI · J. DAVID GLADSTONE INSTITUTES · PI Sudha Krishnamurthy, Melanie Maria Ott · 2014 to 2026
$1.1MNHGRI NIH HHS R01 HG008140NHLBI NIH HHS R25 HL121037NIAID NIH HHS R01 AI155984NIGMS NIH HHS T32 GM007281NIGMS NIH HHS T32 GM136547NIGMS NIH HHS T32 GM150375
Abstract
γδ T cells are potent anticancer effectors with the potential to target tumours broadly, independent of patient-specific neoantigens or human leukocyte antigen background
Indexed as
CRISPR-Cas SystemsGene EditingNeoplasmsReceptors, Antigen, T-Cell, gamma-deltaT-LymphocytesAMP-Activated Protein KinasesAntigens, CDButyrophilinsCell LineCell MembraneHumansAMP-Activated Protein KinasesAntigens, CDBTN2A1 protein, humanBTN3A1 protein, humanButyrophilinsReceptors, Antigen, T-Cell, gamma-delta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.